Medically reviewed by Drugs.com. Last updated on May 6, 2019.
(byoo PIV a kane lye po SO mal)
- Bupivacaine Liposome
- Bupivacaine Liposome/Pf
- DepoFoam Bupivacaine
- Liposomal Bupivacaine
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Exparel: 1.3% (10 mL, 20 mL)
Brand Names: U.S.
- Local Anesthetic
Blocks both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction.
Systemic absorption varies; dependent on dose, route of administration, and vascularity of administration site
Hepatic via conjugation; major metabolite pipecoloxylidine (PPX; inactive)
Urine (~6% unchanged)
Onset of Action
Rapid (Hu 2013)
Time to Peak
Within 1 hour (initial peak); 12 to 36 hours (second peak) (Hu 2013)
Duration of Action
Local: Up to 72 hours (Hu 2013); Systemic: Plasma levels can persist for 96 hours after local administration and 120 hours after interscalene brachial plexus nerve block.
13 to 34 hours (Hu 2013)
Special Populations: Renal Function Impairment
Renal impairment may reduce bupivacaine elimination increasing systemic exposure.
Special Populations: Hepatic Function Impairment
Severe impairment may reduce bupivacaine metabolism increasing systemic exposure.
Use: Labeled Indications
Analgesia, postsurgical: Single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia.
Obstetrical paracervical block anesthesia
Note: Bupivacaine (liposomal) is not bioequivalent to bupivacaine hydrochloride; dosing conversion from bupivacaine hydrochloride to bupivacaine (liposomal) or vice versa is not possible.
Local anesthesia: Infiltration: Single dose: Dose is based on size of surgical site, volume required to cover the area, and individual patient factors (maximum dose: 266 mg [20 mL]). General dosage guidance for bunionectomy and hemorrhoidectomy provided below:
Bunionectomy: 7 mL of undiluted bupivacaine (liposomal) infiltrated into the tissues surrounding the osteotomy and 1 mL of undiluted bupivacaine (liposomal) infiltrated into the subcutaneous tissue of the surgical site (total dose = 106 mg [8 mL])
Hemorrhoidectomy: 30 mL of diluted bupivacaine (liposomal) (20 mL diluted with 10 mL NS) divided and infiltrated as 6 injections of 5 mL each (total dose = 266 mg [20 mL]) around the anal sphincter.
Regional analgesia: Interscalene brachial plexus nerve block: Single dose:
Total shoulder arthroplasty or rotator cuff repair: 133 mg (10 mL)
Refer to adult dosing.
Invert vial several times prior to withdrawing contents to resuspend particles. May dilute with NS or LR up to a final concentration of 0.89 mg/mL (ie, a 1:14 dilution by volume). Use only NS or LR for dilution; use of water or other hypotonic agents will disrupt liposomal particles. Do not admix with other local anesthetics (except for bupivacaine hydrochloride) or drugs. Bupivacaine hydrochloride may be mixed in the same syringe as bupivacaine (liposomal) as long as the milligram ratio of bupivacaine hydrochloride to bupivacaine (liposomal) does not exceed 1:2.
Administer undiluted or diluted. Inject slowly (1 to 2 mL per injection) into the surgical site using a ≥25 gauge needle with frequent aspiration prior to and during administration; do not filter. Do not administer epidurally, intrathecally, intravascularly, intra-articularly, or as a regional nerve block (except interscalene brachial plexus nerve block). Do not allow bupivacaine (liposomal) to come into contact with antiseptics (eg, povidone iodine) in solution; when a topical antiseptic is applied, allow site to dry prior to injection.
Non-bupivacaine-based local anesthetics may cause an immediate release of bupivacaine (liposomal) if administered together locally; therefore, bupivacaine should be administered no sooner than 20 minutes after injection of lidocaine. Do not administer other local anesthetics or other formulations of bupivacaine within 96 hours following bupivacaine (liposomal) administration; bupivacaine hydrochloride may be administered simultaneously in the same syringe or injected immediately before bupivacaine (liposomal) as long as the milligram ratio of bupivacaine hydrochloride to bupivacaine (liposomal) does not exceed 1:2.
Store intact vials at 2°C to 8°C (36°F to 46˚F); may also store at 20°C to 25°C (68°F to 77°F) for up to 30 days (do not re-refrigerate); do not heat or autoclave vials before use. Following withdrawal from the vial, store at 20°C to 25°C (68°F to 77°F) up to 4 hours prior to administration. Diluted suspensions must be used within 4 hours of preparation. Do not freeze or expose to high temperature (>40°C [104°F]) for an extended period of time or administer if suspected of being frozen or exposed to high temperatures. Discard any unused portion.
Bupivacaine: May enhance the adverse/toxic effect of Bupivacaine (Liposomal). Management: Bupivacaine may be administered immediately before, or administered in the same admixture syringe as liposomal bupivacaine as long as the ratio of the milligram dose of bupivacaine to liposomal bupivacaine does not exceed 1:2. Consider therapy modification
Hyaluronidase: May enhance the adverse/toxic effect of Local Anesthetics. Monitor therapy
Lidocaine (Systemic): May enhance the adverse/toxic effect of Bupivacaine (Liposomal). Management: Liposomal bupivacaine should not be administered with topical lidocaine. Liposomal bupivacaine may be administered 20 minutes or more after the administration of lidocaine. Consider therapy modification
Local Anesthetics: May enhance the adverse/toxic effect of Bupivacaine (Liposomal). Management: Liposomal bupivacaine should not be administered with local anesthetics. Liposomal bupivacaine may be administered 20 minutes or more after the administration of lidocaine, but the optimal duration of dose separation for other local anesthetics is unknown Exceptions: Benzocaine; Benzydamine; Cocaine (Topical); Dibucaine; Dyclonine; Ethyl Chloride; Hexylresorcinol; Lidocaine (Ophthalmic); Lidocaine (Topical); Pramoxine; Proparacaine; Tetracaine (Ophthalmic); Tetracaine (Topical). Avoid combination
Methemoglobinemia Associated Agents: May enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. Monitor therapy
Neuromuscular-Blocking Agents: Local Anesthetics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Monitor therapy
Technetium Tc 99m Tilmanocept: Local Anesthetics may diminish the diagnostic effect of Technetium Tc 99m Tilmanocept. Management: Avoid mixing and simultaneously co-injecting technetium Tc 99m tilmanocept with local anesthetics. This interaction does not appear to apply to other uses of these agents in combination. Monitor therapy
Central nervous system: Motor dysfunction (12% to 21%)
Gastrointestinal: Nausea (<40%), vomiting (28%), constipation (2% to 22%)
Miscellaneous: Fever (2% to 23%)
1% to 10%:
Cardiovascular: Hypertension (<10%; includes procedural hypertension), hypotension (7%), procedural hypotension (4%), tachycardia (4%), peripheral edema (2% to 3%), sinus tachycardia (2% to 3%), atrial fibrillation (<2%), bradycardia (<2%), bundle branch block (<2%), cardiac arrhythmia (<2%), deep vein thrombosis (<2%), edema (<2%), first degree atrioventricular block (<2%), oxygen saturation decreased (<2%), orthostatic hypotension (<2%), palpitations (<2%), presyncope (<2%), prolonged QT interval on ECG (<2%), sinus bradycardia (<2%), supraventricular extrasystole (<2%), syncope (2%), ventricular premature contractions (<2%), ventricular tachycardia (<2%)
Central nervous system: Insomnia (2% to <10%), procedural pain (2% to <10%), headache (4% to 8%), dizziness (≤6%; includes postural dizziness), confusion (5%), fatigue (5%), drowsiness (2% to 5%), hypoesthesia (2% to 4%), anxiety (3%), sensation of cold (3%), falling (2% to 3%), feeling hot (2%), mobility disorder (decreased: 2%), sensation disorder (sensory loss: 2%), agitation (<2%), chills (<2%), delirium (<2%), depression (<2%), hyperthermia (<2%), myasthenia (<2%), pain (<2%), paresthesia (<2%), restlessness (<2%), sedation (<2%), lethargy (1%)
Dermatologic: Hyperhidrosis (5%), pruritus (3%), cellulitis (<2%), diaphoresis (<2%), erythema (<2%), increased wound secretion (<2%), pallor (<2%), pruritic rash (<2%), skin blister (<2%), skin rash (<2%), urticaria (<2%)
Gastrointestinal: Dysgeusia (7%), oral hypoesthesia (3% to 4%), hiccups (1% to 2%)
Genitourinary: Urinary retention (8%), dysuria (<2%), urinary incontinence (<2%)
Hematologic & oncologic: Acute posthemorrhagic anemia (2% to <10%; postoperative), anemia (6%), bruise (≤2%), hematoma (<2%), leukocytosis (<2%), postoperative hematoma (≤2%)
Hepatic: Increased liver enzymes (4%), increased serum aspartate aminotransferase (3%), increased serum alanine aminotransferase (1%)
Hypersensitivity: Fixed drug eruption (<2%), hypersensitivity reaction (<2%)
Infection: Fungal infection (2%)
Local: Localized edema (incision site: <2%)
Neuromuscular & skeletal: Back pain (<10%), muscle spasm (<10%), muscle twitching (8%), arthralgia (<2%), asthenia (<2%), joint swelling (<2%), laryngospasm (<2%), musculoskeletal pain (<2%), neck pain (<2%), tremor (<2%)
Ophthalmic: Blurred vision (<2%), decreased visual acuity (<2%)
Otic: Auditory impairment (<2%), tinnitus (<2%)
Renal: Increased serum creatinine (2%)
Respiratory: Hypoxia (1% to 2%), apnea (<2%), atelectasis (<2%), cough (<2%), dyspnea (<2%), pulmonary infiltrates (<2%), pneumonia (<2%), pulmonary infection (<2%), respiratory depression (<2%), respiratory failure (<2%)
Miscellaneous: Procedural complications (postprocedural swelling: 2%), dehiscence (<2%)
<1%, postmarketing, and/or case reports: Paralysis, seizure
Concerns related to adverse effects:
• CNS effects: CNS effects (including excitation and/or depression) may occur, possibly leading to convulsions, unconsciousness, and/or respiratory arrest; may be related to total dose administered, route of administration, and physical status of patient; monitor for CNS-related changes or alterations in consciousness after each injection. Additionally, use of local anesthetics have been associated with neurologic effects following infiltration of soft tissue (persistent anesthesia, paresthesia weakness, paralysis), which may be irreversible.
• CNS toxicity: Careful and constant monitoring of the patient's state of consciousness should be done following each local anesthetic injection; at such times, restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, twitching, tinnitus, dizziness, blurred vision, tremors, depression, or drowsiness may be early warning signs of CNS toxicity. Sensory and/or motor loss is temporary and varies and may last up to 5 days.
• Cardiovascular toxicity: Serious and fatal cardiovascular system reactions (eg, decreased cardiac output and arterial blood pressure, atrioventricular block, ventricular arrhythmias, cardiac arrest) may occur with toxic concentrations.
• Hypersensitivity reactions: Allergic-type reactions (eg, angioneurotic edema [including laryngeal edema], dizziness, elevated temperature, excessive sweating, nausea, syncope, tachycardia, pruritus, erythema, sneezing, urticaria, vomiting) and possibly anaphylactoid-like symptoms (including severe hypotension) have been reported (rare); cross-sensitivity among amide-type local anesthetics has been reported.
• Intra-articular infusion related chondrolysis: Continuous intra-articular infusion of local anesthetics after arthroscopic or other surgical procedures is not an approved use; chondrolysis (primarily in the shoulder joint) has occurred following infusion, with some cases requiring arthroplasty or shoulder replacement.
• Methemoglobinemia: Has been reported with local anesthetics; clinically significant methemoglobinemia requires immediate treatment along with discontinuation of the anesthetic and other oxidizing agents. Onset may be immediate or delayed (hours) after anesthetic exposure. Patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, exposure to oxidizing agents or their metabolites, or infants <6 months of age are more susceptible and should be closely monitored for signs and symptoms of methemoglobinemia (eg, cyanosis, headache, rapid pulse, shortness of breath, lightheadedness, fatigue).
• Respiratory arrest: Local anesthetics have been associated with rare occurrences of sudden respiratory arrest.
• Seizures: Convulsions due to systemic toxicity leading to cardiac arrest have been reported with local anesthetics.
• Cardiovascular disease: Use with caution in patients with cardiovascular disease; patients with impaired cardiovascular function are less able to compensate for functional changes associated with AV conduction prolongation produced by bupivacaine.
• Hepatic impairment: Use with caution in patients with hepatic impairment; patients with severe impairment may be at greater risk for toxicity.
• Renal impairment: Use with caution in patients with renal impairment; may be at greater risk for toxicity.
Concurrent drug therapy issues:
• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.
• Appropriate use: Avoid intravascular, epidural, intrathecal, intra-articular, and regional nerve block (except interscalene brachial plexus nerve block) injections. Not indicated for preincisional or preprocedural locoregional anesthetic techniques that require deep and complete sensory block. Do not administer other local anesthetics or other formulations of bupivacaine within 96 hours following bupivacaine (liposomal) administration. Aspiration should must be performed frequently prior to and during administration; the needle must be repositioned until no return of blood can be elicited by aspiration; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided.
• Product interchangeability: Bupivacaine hydrochloride is not bioequivalent to bupivacaine (liposomal); dosing conversion from bupivacaine hydrochloride to bupivacaine (liposomal) and vice versa is not possible.
• Trained personnel: Clinicians using local anesthetic agents should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use.
Cardiovascular and respiratory (adequacy of ventilation) vital signs, state of consciousness; signs of CNS toxicity, pain relief.
Adverse events have been observed in animal reproduction studies. Bupivacaine crosses the placenta. Not recommended for use in pregnancy. Use in obstetrical paracervical block anesthesia is contraindicated; may cause fetal bradycardia and death.
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience insomnia, muscle spasms, hiccups, or back pain. Have patient report immediately to prescriber severe headache; dizziness; passing out; vision changes; signs of methemoglobinemia (blue or gray color of the lips, nails, or skin; abnormal heartbeat; seizures; severe dizziness or passing out; severe headache; fatigue; loss of strength and energy; or shortness of breath); change in balance; agitation; anxiety; change in speech; change in taste; lightheadedness; fatigue; confusion; blurred vision; tinnitus; tremors; twitching; depression; seizures; nausea; vomiting; chills; small pupils; chest pain; tachycardia; abnormal heartbeat; sneezing; sweating a lot; joint pain; joint rigidity; weakness, numbness, or tingling; swelling of arms or legs; difficult urination; or severe loss of strength and energy (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.
More about bupivacaine liposome
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- En Español
- 20 Reviews
- Drug class: local injectable anesthetics